期刊
ACS OMEGA
卷 6, 期 25, 页码 16584-16591出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsomega.1c01797
关键词
-
资金
- DalCor Pharmaceuticals Canada
The study revealed that Dalcetrapib could effectively inhibit SARS-CoV-2 viral replication by binding to the catalytic site of 3CL protease and stabilizing the protease-drug interaction. This finding paves the way for its clinical evaluation in the treatment of COVID-19.
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 3CL protease is a promising target for inhibition of viral replication by interaction with a cysteine residue (Cys145) at its catalytic site. Dalcetrapib exerts its lipid-modulating effect by binding covalently to cysteine 13 of a cholesteryl ester transfer protein. Because 12 free cysteine residues are present in the 3CL protease, we investigated the potential of dalcetrapib to inhibit 3CL protease activity and SARS-CoV-2 replication. Molecular docking investigations suggested that dalcetrapib-thiol binds to the catalytic site of the 3CL protease with a delta G value of -8.5 kcal/mol. Dalcetrapib inhibited both 3CL protease activity in vitro and viral replication in Vero E6 cells with IC50 values of 14.4 +/- 3.3 mu M and an EC50 of 17.5 +/- 3.5 mu M (mean +/- SD). Near-complete inhibition of protease activity persisted despite 1000-fold dilution after ultrafiltration with a nominal dalcetrapib-thiol concentration of approximately 100 times below the IC50 of 14.4 mu M, suggesting stable protease-drug interaction. The inhibitory effect of dalcetrapib on the SARS-CoV-2 3CL protease and viral replication warrants its clinical evaluation for the treatment of COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据